Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine

Journal of Clinical Psychopharmacology

Volumn 23, Issue 4, 2003, Pages 349-357

  Hall, Judith ^a,b   Naranjo, Claudio A ^a,b   Sproule, Beth A ^a   Herrmann, Nathan ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOCHROME P450 3A4; DINORCITALOPRAM; FLUOXETINE; NEFAZODONE; NORCITALOPRAM; NORFLUOXETINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; HALF LIFE TIME; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL; SEDATION; STATISTICAL SIGNIFICANCE;

ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; CITALOPRAM; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FLUOXETINE; HALF-LIFE; HUMANS;

EID: 0042634397     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000085407.08426.e1     Document Type: Article

References (33)

1. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270: 414-423.
2. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32:210-258.
3. Sproule BA, Naranjo CA, Brenmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997;33:454-471.
4. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol. 1994;38:23-31.
5. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-131.
6. Schmider J, Brockmoller J, Arold G, et al. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics. 1999;9:725-734.
7. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berlin). 1998;139:269-273.
8. Hassan PC, Sproule BA, Naranjo CA, et al. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol. 2000;20:150-158.
9. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry. 1993;54(suppl):4-11.
10. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol. 1998;18:256.
11. Gorski JC, Jones DR, Hamman MA, et al. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica. 1999;29:931-944.
12. Maier W, Falkai P. The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. Int Clin Psychopharmacol. 1999;14(suppl 2):S1-S6.
13. Kessler RC, Stang PE, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry. 1998;55:801-808.
14. Greenblatt DJ, von Moltke LL, Schmider J, et al. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol. 1996;36:792-798.
15. Naranjo CA, Sproule BA, Knoke DM. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1999;14(suppl 2):S35-S47.
16. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther. 1992;52:479-486.
17. Lasher TA, Fleishaker JC, Steenwyk RC, et al. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berlin). 1991;104: 323-327.
18. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999;46:839-849.
19. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol. 2001;41:1149-1179.
20. Chan WK, Nguyen LT, Miller VP, et al. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci. 1998;62:L135-L142.
21. Yasui N, Kondo T, Furukori H, et al. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berlin). 2000;150:185-190.
22. Greenblatt DJ, Harmatz JS, Dorsey C, et al. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther. 1988;44:326-334.
23. Oyehaug E, Ostensen ET, Salvesen B. Determination of the antidepressant agent citalopram and metabolites in plasma by liquid chromatography with fluorescence detection. J Chromatogr. 1982;227: 129-135.
24. McCormick SR, Nielsen J, Jatlow P. Quantification of alprazolam in serum or plasma by liquid chromatography. Clin Chem. 1984;30: 1652-1655.
25. Sidhu J, Priskorn M, Poulsen M, et al. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality. 1997;9:686-692.
26. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1975.
27. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16:143-166.
28. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther. 1996;59:514-519.
29. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther. 2000;67:335-341.
30. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther. 1998;64:237-247.
31. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol. 1995;15:399-408.
32. Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet. 1993;24:453-471.
33. Nolting A, Abramowitz W. Lack of interaction between citalopram and the CYP3A4 substrate triazolam. Pharmacotherapy. 2000;20: 750-755.